Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma-Reference-Cited by-同舟云学术

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma

Published:2024-01-01 Issue:1 Volume:42 Page:26-37
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Leypoldt Lisa B.¹^ORCID,Tichy Diana²^ORCID,Besemer Britta³,Hänel Mathias⁴,Raab Marc S.⁵^ORCID,Mann Christoph⁶^ORCID,Munder Markus⁷^ORCID,Reinhardt Hans Christian⁸,Nogai Axel⁹,Görner Martin¹⁰,Ko Yon-Dschun¹¹,de Wit Maike¹²,Salwender Hans¹³^ORCID,Scheid Christof¹⁴^ORCID,Graeven Ullrich¹⁵^ORCID,Peceny Rudolf¹⁶,Staib Peter¹⁷,Dieing Annette¹⁸,Einsele Hermann¹⁹,Jauch Anna²⁰,Hundemer Michael²¹,Zago Manola²²,Požek Ema²,Benner Axel²^ORCID,Bokemeyer Carsten¹^ORCID,Goldschmidt Hartmut²³^ORCID,Weisel Katja C.¹^ORCID

Affiliation:

1. Department of Hematology, Oncology and Bone Marrow Transplantation With Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

2. Division of Biostatistics, German Cancer Research Center (DKFZ) Heidelberg, Heidelberg, Germany

3. Department of Hematology, Oncology, Immunology and Rheumatology, University Hospital of Tuebingen, Tuebingen, Germany

4. Department of Hematology, Oncology and Bone Marrow Transplantation, Klinikum Chemnitz, Chemnitz, Germany

5. Internal Medicine V and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany

6. Department of Hematology, Oncology and Immunology, University Hospital of Gießen and Marburg, Marburg, Germany

7. Department of Internal Medicine III, University Medical Center Mainz, Mainz, Germany

8. Department of Hematology and Stem Cell Transplantation, University Hospital Essen, University Duisburg-Essen, German Cancer Consortium (DKTK partner site Essen), Essen, Germany

9. Department of Internal Medicine, Charité—University Medicine Berlin, Berlin, Germany

10. Department of Hematology, Oncology and Palliative Care, Klinikum Bielefeld Mitte, Bielefeld, Germany

11. Department of Internal Medicine, Hematology and Oncology, Johanniter Krankenhaus Bonn, Bonn, Germany

12. Department of Internal Medicine, Hematology, Oncology and Palliative Medicine, Vivantes Klinikum Neukölln, Berlin, Germany

13. Asklepios Tumorzentrum Hamburg, AK Altona and AK St Georg, Hamburg, Germany

14. Department of Internal Medicine I, University Hospital Cologne, Cologne, Germany

15. Department of Hematology, Oncology and Gastroenterology, Kliniken Maria Hilf, Mönchengladbach, Germany

16. Department of Oncology, Hematology and Stem Cell Transplantation, Klinikum Osnabrück, Osnabrück, Germany

17. Department of Hematology and Oncology, St Antonius Hospital Eschweiler, Eschweiler, Germany

18. Department of Hematology and Oncology, Vivantes Klinikum am Urban, Berlin, Germany

19. Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany

20. Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany

21. Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany

22. Center for Clinical Trials, University Hospital of Tuebingen, Tuebingen, Germany

23. Internal Medicine V, GMMG-Studygroup at University Hospital Heidelberg, Heidelberg, Germany

Abstract

High, sustainable MRD negativity rates with Isa-KRd in newly diagnosed high-risk multiple myeloma (CONCEPT trial)

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.23.01696

Reference37 articles.

1. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

2. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

3. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

4. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

5. Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Subsequent therapy and outcomes in patients with newly diagnosed multiple myeloma experiencing disease progression after quadruplet combinations;British Journal of Haematology;2024-01-30

2. Glücksklee, the Quad, and High-Risk Myeloma;Journal of Clinical Oncology;2024-01-01

3. Upfront or Deferred Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Triplet and Quadruplet Induction and Minimal Residual Disease/Risk-Adapted Therapy;Cancers;2023-12-05